Marie Beaudin

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 6

Top Topics

Intellectual Disability

Cognitive Impairment

Dna Damage Response

Top Venues

Expert review of neurotherapeutics

Nature reviews. Neurology

Journal of clinical medicine

Cerebellum (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Marie Beaudin, Nicolas Dupre, Mario Manto
The importance of synthetic pharmacotherapy for recessive cerebellar ataxias. Expert review of neurotherapeutics (2024)
Marie Beaudin, Nicolas Dupre, Mario Manto
The importance of synthetic pharmacotherapy for recessive cerebellar ataxias. Expert review of neurotherapeutics 24 (9) (2024)
Marie Beaudin, Tahereh Kamali, Whitney Tang, Katharine A Hagerman, Sally Dunaway Young, Lisa Ghiglieri, Dana M Parker, Benoit Lehallier, Carolina Tesi-Rocha, Jacinda B Sampson, Tina Duong, John W Day
Cerebrospinal Fluid Proteomic Changes after Nusinersen in Patients with Spinal Muscular Atrophy. Journal of clinical medicine 12 (20) (2023)
Marie Beaudin, Mario Manto, Jeremy D Schmahmann, Massimo Pandolfo, Nicolas Dupre
Recessive cerebellar and afferent ataxias - clinical challenges and future directions. Nature reviews. Neurology 18 (5) (2022)
Marie Beaudin, Antoni Matilla-Dueñas, Bing-Weng Soong, Jose Luiz Pedroso, Orlando G Barsottini, Hiroshi Mitoma, Shoji Tsuji, Jeremy D Schmahmann, Mario Manto, Guy A Rouleau, Christopher Klein, Nicolas Dupre
The Classification of Autosomal Recessive Cerebellar Ataxias: a Consensus Statement from the Society for Research on the Cerebellum and Ataxias Task Force. Cerebellum (London, England) 18 (6) (2020)
Marie Beaudin, Leila Sellami, Christian Martel, Lydia Touzel-Deschênes, Gabrielle Houle, Laurence Martineau, Kevin Lacroix, Andréane Lavallée, Nicolas Chrestian, Guy A Rouleau, François Gros-Louis, Robert Jr Laforce, Nicolas Dupre
Characterization of the phenotype with cognitive impairment and protein mislocalization in SCA34. Neurology. Genetics 6 (2) (2020)